The dopamine transporter (DAT) plays a crucial role in dopaminergic neurotransmission as it clears the extracellular space of dopamine (DA) and thus controls the concentration of active neurotransmitter. Genetic association studies have reported a variable number of tandem repeat polymorphisms in the 3 0 -noncoding region of the DAT gene implicating this protein in the development of various psychiatric disorders. In a sample of bipolar patients, two rare missense substitutions (A559V and E602G) have been identified, one of which (E602G) was inherited by the patient from her affected father. None of these mutations had been identified in any control subjects of this survey. Using a heterologous cellular expression system, we have analysed possible consequences of these mutations on functional properties of the encoded DAT protein. DA transport measurements and antagonist binding revealed that the A559V mutant protein is fully functional, whereas the E602G mutant is not. Further analyses by confocal microscopy showed that the E602G protein is transcribed and translated but not delivered to the cell surface. Taken together, our results suggest that this missense mutation has functional consequences thus supporting the need to screen larger samples of patients and their relatives for this rare but bipolar disorder-associated mutation in the DAT gene.
Dysbalance in dopaminergic neurotransmission has been implicated in the aetiology of a variety of psychiatric disorders, including schizophrenia, bipolar affective disorder, attention deficit hyperactivity disorder (ADHD), drug addiction, and also Parkinson's disease. In the central nervous system, dopaminergic neurotransmission is terminated by high-affinity reuptake of the neurotransmitter from the synaptic cleft. This transport mechanism is mediated by a specific dopamine transporter protein, DAT. 1, 2 As the dopamine (DA) transporter clears the synaptic cleft of the neurotransmitter, it plays a crucial role by controlling the concentration of free, active neurotransmitter in the extracellular space. Thus, drugs affecting DAT function such as cocaine or amphetamines enhance dopaminergic signalling, which in turn can result in hyperactivity and other behavioural changes. The importance of correct DAT function for normal behaviour has been impressively demonstrated in DAT knockout mice. 3, 4 Owing to the lack of the transporter protein, these animals have ongoing hyperdopaminergic neurotransmission resulting in hyperactive behaviour. Consequently, the psychostimulants cocaine and amphetamines affect neither DA release and uptake nor locomotor activity in these mice. The human DAT gene maps to chromosome 5p15.3, contains 15 exons and carries a variable number of tandem repeat (VNTR) polymorphisms in the 3 0 -untranslated region. [5] [6] [7] [8] [9] [10] These VNTRs as well as haplotypes of various 5 0 and intronic regions have been shown to affect DAT expression at the transcriptional level. [11] [12] [13] [14] Genetic association studies have implicated the DAT gene in the aetiology of psychiatric diseases such as ADHD, [15] [16] [17] [18] schizoid/avoidant behaviour, 19 and bipolar affective disorders. [20] [21] [22] In a study comprising 45 patients with bipolar affective disorder and 46 healthy controls, screening of the complete coding regions of the human DAT identified two rare missense substitutions, Ala559Val and Glu602Gly (A559V, E602G), each in single bipolar patients but not in controls. 23 DAT is a member of the Na þ /Cl À -dependent neurotransmitter transporter family, which also includes transporters for serotonin, noradrenaline, GABA, and glycine. [24] [25] [26] The members of this neuro-transmitter transporter family are integral transmembrane proteins and share a common putative 12 transmembrane domain (TMD) structure. Heterologous expression of the cloned transporter proteins in Xenopus oocytes and mammalian cells generates specific neurotransmitter uptake, which exhibits a pharmacological profile similar to that of the native transport systems. Thus, transfection with a single cDNA confers expression of functional neurotransmitter transport of well-defined pharmacology onto non-neuronal cells. Here, we have exploited this methodology to characterise the recombinant DATs carrying the mutations A559V and E602G, individually, and to compare them with the activity of the heterologously expressed wild-type (wt) DAT. Whereas the A559V mutant behaves similarly to the wt, the E602G mutation severely hampered DAT cell surface expression, which would imply a decrease of DA clearance from the extracellular space in carriers of this mutation. Antibody against DAT was a rabbit anti-DA transporter polyclonal antibody (Santa Cruz, USA) the secondary antibody (Alexa 555-conjugated donkey anti-rabbit IgG) was from Molecular Probes (USA).
Materials and methods

Materials
Construction of mutants
The cDNA of human DAT was excised from pBluescript-hDAT (which was a generous gift of S Amara) and cloned via KpnI and HindIII into pcDNA3.1(-)/Myc-His. Mutants were generated by PCR with oligos sense 5 0 -GACTGGGCCAACGTGCTGGG and antisense 5 0 -GACC CAGCCCAGCACGTTGG for hDAT-A559V, respectively, and oligos sense 5 0 -GAAGGACCGTGGGCTGGTGGAC and antisense 5 0 -TCCACCAGCCCACGGTCCTTC for hDAT-E602G, respectively (mutant codons are underlined). Amplification was performed with the respective vector primers using Taq polymerase. Conditions for all reactions were 941C for 30 s, 591C for 30 s, and 721C for 1 min, with 10 min extension time after 34 cycles. Products were verified by sequencing.
Cell culture HEK293 cells were transfected with the cDNA of wt-DAT, A559-DAT, and E602G-DAT, respectively, by calcium phosphate precipitation as described earlier. 27 After transfection, the cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 mg/ml), at 371C in 95% humidified air with 5% CO 2 . Selection of clonal lines permanently expressing the wt and mutant DAT proteins was performed as described earlier. 28, 29 Stably transfected cells were selected with G418 (1 mg/ml) and maintained in DMEM supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (100 mg/ml), and G418 (500 mg/ml).
[ 3 H]DA transport measurement DA uptake was performed as described previously. 30 Briefly, HEK293 cells were plated into 24-well dishes (2 cm in diameter), which had been treated with poly-L-lysine (0.1 mg/ml) and allowed to grow to 50-70% confluency. Culture medium was replaced by TB1 buffer (200 ml) containing 120 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES (pH 7.5) and various concentrations of DA (0.25-5.125 mM) using 250 nM [ 3 H]DA as tracer. After 6 min at room temperature, the medium was removed quickly and cells were washed twice with ice-cold TB1 before lysing with 10% (w/v) SDS. Radioactivity was determined by scintillation counting. Specific DA uptake is determined as the difference between DATmediated uptake and nonsaturable diffusion into nontransfected HEK293 cells, which did not differ from diffusion into mock-transfected cells. All uptake data represent the means of quadruplicate determinations; each experiment was repeated at least three times. Data were analysed by nonlinear regression analysis program (Graph Pad, Prism), which fitted sigmoidal uptake curves to the following equations
, V represents transport rate, V max maximal transport rate, K M the Michaelis-Menten constant, and S substrate concentration.
Membrane preparations
Membranes from wt-DAT and mutant DAT-expressing cell lines were prepared as follows: cells in 10 cm dishes were washed once with phosphate-buffered saline (PBS) (without Ca 2 þ /Mg 2 þ ), 2 ml PBS was then added to the cell monolayer and the cells scraped off and homogenised with 10 strokes of a Dounce glass homogeniser. This cell lysate was then centrifuged at 1500 Â g for 3 min and the supernatant centrifuged at 41 000 Â g for a further 30 min. The resulting pellet was suspended in 120 ml of PBS containing 5% (v/v) glycerol per 10 cm plate using 10 strokes of a Dounce glass homogeniser. The protein concentration was determined using the Markwell assay. 31 The membranes were stored in aliquots at À801C. H]WIN35,428 to cell membranes was performed as described earlier. 30 Saturation binding was performed at room temperature using 30 mg membrane protein in a total volume of 200 ml of assay buffer (125 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES, pH 7.5) containing 0.5-12 nM of [ Immunofluorescence and confocal analysis Subconfluent cells were grown on coverslips and fixed with 4% paraformaldehyde for 15 min. After fixation, cells were permeabilised with 0.1% saponin. Antibodies were incubated in PBS containing 0.2% fish skin gelatin and 0.01% saponin. Coverslips were mounted in fluorescent mounting medium (DakoCytomation, Denmark) and confocal images were acquired on a Leica DM IRE2 confocal microscope using a Â 63 oil planachromat lens (NA 1.3; Leica, Germany).
Results
Substrate transport by and antagonist binding to HEK293 cells stably expressing wt-DAT, A559V-DAT, and E602G-DAT In order to compare [ (Table 1) . In contrast, none of all clonal lines selected for stable expression of the E602G-DAT mutant revealed measurable DA transport or antagonist-binding capacity.
Immunocytochemical analyses of HEK293 cells stably expressing wt-DAT, A559V-DAT, and E602G-DAT As described above, it was possible to isolate several clonal cell lines after transfection with the wt-DAT and mutant DAT cDNAs under the selection of the antibiotic G418 at a concentration of 500 mg/ml. To investigate why stable transfection with the E602G mutant allows isolation of stable lines but does not confer DAT function to the respective clonal lines, we compared the expression of wt-DAT and the two mutants by confocal microscopy using an antibody against an intracellular epitope of the transporter. Consequently, no immunoreactive signal could be obtained in the absence of detergents (not shown). However, in the presence of 0.1% saponin, in cells stably expressing wt-DAT, the antibodies labelled the plasma membrane as well as punctuate structures in the perinuclear region and cell periphery, most likely the Golgi complex and post-Golgi transport vesicles containing DAT. A comparable staining pattern was observed for all clonal lines expressing the A559V mutant protein (Figure 1) . In contrast, all cells stably expressing the E602G mutant revealed a distinct staining of globular structures in the perinuclear region and throughout the cell body; however, staining of the plasma membrane was not detected (Figure 1 ). This indicates that the correct delivery of the E602G protein to the cell surface is distorted in cells expressing this mutant and consequently neither antagonist binding nor substrate transport can occur at these cells.
Discussion
Altered dopaminergic neurotransmission has been implicated in the aetiology of a variety of psychiatric conditions, making the DAT an attractive candidate gene for molecular genetic studies in those disorders. Genetic association studies using the VNTR in the 3 0 region of the DAT gene to implicate this transporter in bipolar disorder have been contradictory. Whereas linkage and family-based association studies had suggested a role of the DAT gene in bipolar disorders, [20] [21] [22] this was not the case in some other studies. [32] [33] [34] [35] [36] [37] [38] A recent study investigated whether so far unknown mutations in the coding region of the DAT gene being in linkage disequilibrium might account for the observed associations. Here, two variants of possible functional significance (A559V and E602G) have been identified each in two single bipolar individuals, which were not found in any of the controls of this survey. 23 Further examination suggested that the A559V variant does not segregate with the disorder since the affected mother, brother, and maternal aunt were all A559A. 23 In contrast, the female patient carrying the E602G mutant DAT gene had inherited this variant from her father, who also fulfilled DSM-III-R criteria for bipolar disorder.
Here, using a heterologous expression system, we have analysed possible consequences of the A559V and E602G amino-acid exchanges on functional properties of the encoded DAT protein. To this intent, we transfected kidney cells which do not express endogenous DAT protein, with cDNAs encoding the wt-, A559V-and E602G-DAT cDNAs. All clonal lines selected after stable transfection with wt-DAT and A559V-DAT DNA revealed saturable DA uptake and WIN binding. For the E602G-DAT protein we (ii) the E602G-DAT due to its mutation is not expressed on the cell surface; (iii) it is expressed, but not functional. To differentiate these possibilities, we analysed the expression of wt-DAT and the two mutants by confocal microscopy using an antibody against the DA transporter protein. In all cells stably expressing wt-DAT as well as the A559V mutant, immunoreactivity was observed on the plasma membrane as well as in punctuate structures in the perinuclear region and cell periphery. In contrast, in all cells stably expressing the E602G mutant, we found a distinct staining only in the perinuclear region and throughout the cell body, but never on the plasma membrane, indicating that the E602G DAT protein is transcribed and translated but not delivered to the cell surface.
The DAT protein is an integral membrane protein consisting of 12 TMDs with the N-and C-termini exposed to the cytoplasm. By analysing substitution and truncation mutants, the C-terminus had been shown to contain important determinants for intracellular trafficking and surface targeting of the transporter. [39] [40] [41] [42] This domain also contains a di-acidic signal motif '(D/E) Â (D/E)', (D 600 R 601 E 602 ), which has been shown to be required for protein export from the endoplasmatic reticulum. [43] [44] [45] Mutation of either the aspartic or the glutamic acid in this cytoplasmically exposed motif dramatically reduced the rate of ER export of all proteins investigated in these reports. In a recent study, all amino acids of the DAT C-terminus had been replaced by alanine and the resulting mutants were analysed after transient transfection into porcine aortic endothelial (PAE) cells. In this system, the D600A mutant protein was retained in the ER; however, the E602A mutant was also found on the cell surface, suggesting that export of the DAT protein is independent of the DXE motif. 42 Several reasons may account for the discrepancy to our findings here, among others the rate of cell surface expression being dependent on the mode of transfection. In most cells permanently expressing wt-DAT, in addition to its expression on the plasma membrane a certain amount of the protein is always seen in cell structures most likely reflecting ER or Golgi vesicles carrying the transporter on the way to the cell surface; however, in cells stably transfected with the E6022G, mutant plasma membrane staining is not observed. In addition, the choice of cells for analysing the function of recombinant proteins might be important. In this respect, a DAT mutant lacking the C-terminus had been shown to mediate low-affinity dopamine transport when transfected in COS-7 cells. 39 A similar construct, when transfected into HEK293 cells, however, was expressed but not targeted to the cell surface of the cells. 40 Therefore, we assume that the natural occurring E602G mutation in the human DAT gene causes inhibition of transporter cell surface expression in human cells, a finding that also emphasises the validity of the DXE motif for protein export from the ER.
Taken together, here we have shown that a rare missense substitution of the DAT protein, which has been identified in one bipolar patient and her father, is functionally relevant at the molecular level, and the next step is to investigate whether this mutation also has functional effects in heterozygote carriers. In the sample, where the mutation was originally identified, 23 it was found in one out of 45 patients and in none of the 46 control persons. This suggests that the mutation may be a rare, but specific cause in the aetiology of bipolar disorder and it is thus important to screen larger samples of patients, their relatives, and controls for this polymorphism.
